These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 14989461)

  • 21. Genetics and Gene Therapy of Anderson-Fabry Disease.
    Simonetta I; Tuttolomondo A; Di Chiara T; Miceli S; Vogiatzis D; Corpora F; Pinto A
    Curr Gene Ther; 2018; 18(2):96-106. PubMed ID: 29618309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lessons learned from the development of enzyme therapy for Gaucher disease.
    Barranger JA; O'Rourke E
    J Inherit Metab Dis; 2001; 24 Suppl 2():89-96; discussion 87-8. PubMed ID: 11758684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful pregnancy outcome in a patient with Fabry disease receiving enzyme replacement therapy with agalsidase alfa.
    Wendt S; Whybra C; Kampmann C; Teichmann E; Beck M
    J Inherit Metab Dis; 2005; 28(5):787-8. PubMed ID: 16151910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cutaneous complications of Anderson-Fabry disease.
    Giuseppe P; Daniele R; Rita BM
    Curr Pharm Des; 2013; 19(33):6031-6. PubMed ID: 23448454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enzymes as Immunotherapeutics.
    Farhadi SA; Bracho-Sanchez E; Freeman SL; Keselowsky BG; Hudalla GA
    Bioconjug Chem; 2018 Mar; 29(3):649-656. PubMed ID: 29285931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases.
    Ferraz MJ; Marques AR; Appelman MD; Verhoek M; Strijland A; Mirzaian M; Scheij S; Ouairy CM; Lahav D; Wisse P; Overkleeft HS; Boot RG; Aerts JM
    FEBS Lett; 2016 Mar; 590(6):716-25. PubMed ID: 26898341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer.
    Ziegler RJ; Yew NS; Li C; Cherry M; Berthelette P; Romanczuk H; Ioannou YA; Zeidner KM; Desnick RJ; Cheng SH
    Hum Gene Ther; 1999 Jul; 10(10):1667-82. PubMed ID: 10428212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of genes and their responses to enzyme replacement therapy in a Fabry disease mouse model.
    Park ES; Choi JO; Park JW; Lee MH; Park HY; Jung SC
    Int J Mol Med; 2009 Sep; 24(3):401-7. PubMed ID: 19639234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic errors and enzyme replacement strategies.
    Brady RO
    Res Publ Assoc Res Nerv Ment Dis; 1983; 60():181-93. PubMed ID: 6130585
    [No Abstract]   [Full Text] [Related]  

  • 30. The attenuated/late onset lysosomal storage disorders: Therapeutic goals and indications for enzyme replacement treatment in Gaucher and Fabry disease.
    Hollak CE; Weinreb NJ
    Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):205-18. PubMed ID: 25987174
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment prospects of lysosomal storage disorders].
    Reismann P; Tulassay Z
    Orv Hetil; 2008 Jun; 149(25):1171-9. PubMed ID: 18547894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gaucher disease: pathological mechanisms and modern management.
    Jmoudiak M; Futerman AH
    Br J Haematol; 2005 Apr; 129(2):178-88. PubMed ID: 15813845
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enzyme replacement therapy for Gaucher disease.
    Charrow J
    Expert Opin Biol Ther; 2009 Jan; 9(1):121-31. PubMed ID: 19063698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enzyme replacement for lysosomal diseases.
    Brady RO
    Annu Rev Med; 2006; 57():283-96. PubMed ID: 16409150
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gaucher disease: unmet treatment needs.
    Mehta A
    Acta Paediatr; 2008 Apr; 97(457):83-7. PubMed ID: 18339195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of antibodies in enzyme treatments and therapeutic strategies.
    Bigger BW; Saif M; Linthorst GE
    Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):183-94. PubMed ID: 25987172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A new glucocerebrosidase-deficient neuronal cell model provides a tool to probe pathophysiology and therapeutics for Gaucher disease.
    Westbroek W; Nguyen M; Siebert M; Lindstrom T; Burnett RA; Aflaki E; Jung O; Tamargo R; Rodriguez-Gil JL; Acosta W; Hendrix A; Behre B; Tayebi N; Fujiwara H; Sidhu R; Renvoise B; Ginns EI; Dutra A; Pak E; Cramer C; Ory DS; Pavan WJ; Sidransky E
    Dis Model Mech; 2016 Jul; 9(7):769-78. PubMed ID: 27482815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Searching for an additional treatment to slowing the progression of Fabry disease.
    Ravarotto V; Carraro G; Simioni F; Bertoldi G; Pagnin E; Calò LA
    Minerva Med; 2019 Apr; 110(2):176-178. PubMed ID: 30821433
    [No Abstract]   [Full Text] [Related]  

  • 39. Therapy for Gaucher disease: don't stop thinking about tomorrow.
    Sidransky E; LaMarca ME; Ginns EI
    Mol Genet Metab; 2007 Feb; 90(2):122-5. PubMed ID: 17084653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Current management of Fabry disease].
    Cochat P; Liutkus A; Dubourg L; Levade T
    Nephrol Ther; 2006 Jan; 2 Suppl 2():S167-71. PubMed ID: 17373218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.